Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Both Wegovy and Mounjaro are given as weekly injections via pre-filled pens that can be self-administered into the upper arm, ...

As more doctors and patients turn to the latest weight-loss drugs, researchers are trying to figure out which drug is right ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

A new study shows Zepbound beats Wegovy for weight loss. "It's NOT normal to snore; get it checked out. Sleep apnea worsens ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...